Giuseppe Masucci
0000-0002-9583-2306
Karolinska University Hospital
121 papers found
Refreshing results…
Hydrogen peroxide secreted by tumor-derived macrophages down-modulates signal-transducing zeta molecules and inhibits tumor-specific T cell-and natural killer cell-mediated cytotoxicity
New clinical applications of granulocyte-macrophage colony-stimulating factor
Antibodies to Epstein-Barr-Virus in Relation to Clinical Characteristics of Untreated Patients With Hodgkins-Disease
Interleukin 10 pretreatment protects target cells from tumor- and allo- specific cytotoxic T cells and downregulates HLA class I expression
Interferon-γ Enhances Monoclonal Antibody 17-1A-Dependent Neutrophil Cytotoxicity toward Colorectal Carcinoma Cell Line SW11-16
Effect of monoclonal antibody 17-1A and gm-CSF in patients with advanced colorectal carcinoma—long-lasting, complete remissions can be induced
Disease-related differences in antibody patterns against EBV-encoded nuclear antigens EBNA 1, EBNA 2 and EBNA 6
GM-CSF Augments the IL-4 Induced Cytotoxic Activity of Human Peripheral Blood Mononuclear Cells in the Presence of the Mouse Monoclonal Antibody 17–1A
Cytotoxic functions of blood mononuclear cells in patients with colorectal carcinoma treated with mAb 17-1A and granulocyte/macrophage-colony-stimulating factor
Chemotherapy and immunotherapy of colorectal cancer
Patients treated with a monoclonal antibody (ab1) to the colorectal carcinoma antigen 17–1A develop a cellular response (DTH) to the “internal image of the antigen” (ab2)
Therapy of Colorectal Carcinoma with Monoclonal Antibodies (MAb17-1A) Alone and in Combination with Granulocyte Monocyte-Colony Stimulating Factor (GM-CSF)
Interleukin-4 augments the cytotoxic capacity of lymphocytes and monocytes in antibody-dependent cellular cytotoxicity
Granulocyte-monocyte colony-stimulating-factor augments the interleukin-2-induced cytotoxic activity of human lymphocytes in the absence and presence of mouse or chimeric monoclonal antibodies (mAb 17-1A)
Lymphokine Activated Killer (LAK) Cells in Antibody Dependent Cellular Cytotoxicity (ADCC) Using MAb 17-1A: A Combination of Potential Usefulness in Tumor Therapy
Granulocyte-monocyte-colony-stimulating factor augments the cytotoxic capacity of lymphocytes and monocytes in antibody-dependent cellular cytotoxicity
Relationship between clinical stage, histopathology and antibody titers against the second epstein-barr virus nuclear antigen (EBNA-2) in non-Hodgkin's lymphoma patients
Biologic Response Modifiers in the Treatment of Gastrointestinal Malignancies
Mab 17-1A Used for Therapy of Patients with Metastatic Colorectal Carcinomas
Analysis of Epstein-Barr virus-specific and non-specific immune functions in a patient during the development of a non-Hodgkin's lymphoma
Missing publications? Search for publications with a matching author name.